Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galectin-9
- Development stage
- Preclinical
- Lead developer
- Gallop Oncology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Galectin-9 is a member of the galectin family of β-galactoside-binding lectins, characterized by two conserved carbohydrate recognition domains. It serves as a critical regulator of immune homeostasis and tumor-immune interactions. In multiple myeloma research, galectin-9 has been identified as a glycan-modulating adjuvant that binds to B cell surface glycans, subsequently inducing a significant upregulation of SLAMF7 (signaling lymphocytic activation molecule F7) on malignant plasma cells. This mechanism enhances the binding and functional activity of the anti-SLAMF7 monoclonal antibody Elotuzumab, leading to increased natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC). Additionally, galectin-9 is the natural ligand for the TIM-3 (Hepatitis A virus cellular receptor 2) checkpoint receptor, through which it modulates T-cell and myeloid cell functions.
- Other names
- LGALS9LGALS-9LGALS 9Gal-9 proteinGal9 proteinGal 9 proteinHUATLGALS9ALGALS-9ALGALS 9A
02
Targets
HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on galectin-9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galectin-9.